Central Pacific Bank Trust Division Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Central Pacific Bank Trust Division bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 42,427 shares of the company's stock, valued at approximately $935,000.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in shares of Teva Pharmaceutical Industries by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 7,458 shares of the company's stock valued at $164,000 after purchasing an additional 2,297 shares during the period. DGS Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after acquiring an additional 872 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Teva Pharmaceutical Industries by 141.7% during the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company's stock valued at $2,674,000 after acquiring an additional 90,920 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Finally, Sanctuary Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after purchasing an additional 664 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.3 %

Shares of NYSE:TEVA traded down $0.06 during trading on Friday, hitting $21.24. 5,192,046 shares of the company were exchanged, compared to its average volume of 6,659,423. The firm's 50 day moving average price is $18.60 and its 200-day moving average price is $17.87. Teva Pharmaceutical Industries Limited has a 12-month low of $10.75 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The stock has a market capitalization of $24.06 billion, a P/E ratio of -24.99, a PEG ratio of 0.99 and a beta of 0.73.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TEVA has been the subject of several research analyst reports. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. Finally, Barclays raised their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus price target of $20.88.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.